Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) Meeting Abstract
| Authors: | Petrylak, D.; Vogelzang, N. J.; Fradet, Y.; Bajorin, D.; de Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Climent, M. A.; Necchi, A.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Jensen, E.; Puhlmann, M.; Perini, R.; Bellmunt, J.; Choueiri, T. K. |
| Abstract Title: | Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | v298 |
| Language: | English |
| ACCESSION: | WOS:000411324002042 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx371.006 |
| Notes: | Meeting Abstract: 851PD -- Source: Wos |
